At the Annual General Meeting on 30 June 2025, TikoMed elected a new board of directors for the period until the next general meeting. The three members of the interim board elected in April this year will continue their assignments – Göran Groth as Chairman of the Board and Tobhias
Vid den ordinarie bolagsstämman den 30 juni 2025 valde TikoMed en ny styrelse för tiden fram till nästa bolagsstämma. De tre ledamöterna från interimsstyrelsen som valdes i april månad fortsätter sina uppdrag – Göran Groth som styrelseordförande och Tobhias Brandell och Lars Bruce som styrelseledamöter. Utöver dessa valde stämman in
Viken, Sweden July 22nd, 2024: Swedish drug development company TikoMed AB today announced the publication in PLOS ONE of peer-reviewed research providing additional support that their low molecular weight dextran sulfate compound ILB® is safe and well tolerated in patients with ALS. Eleven patients participated in the prospective, single-arm, open-label,
Oslo, June 25th, 2024. The Division of Clinical Neuroscience at Oslo University Hospital and the Swedish drug development company TikoMed have recently signed a research collaboration agreement. Common ambition for the parties is for their collaboration to lead to more knowledge and better treatment options for patients diagnosed with Amyotrophic
Viken, Sweden – October 25, 2023 – Swedish biopharmaceutical company TikoMed AB today announced the appointment of Professor Adriano Chiò, of the University of Torino and the Città della Salute e della Scienza Hospital as the fourth member of its newly formed Scientific Advisory Board. Adriano Chiò is a neurologist
Viken – October 11, 2023 – Swedish biopharmaceutical company TikoMed AB today announced the appointment of Professor Jeremy Shefner, MD, PhD at the Gregory W. Fulton ALS & Neuromuscular Disease Center, the Department of Neurology at Barrow Neurological Institute in Phoenix, Arizona, USA as the third member of its newly-formed